Therapeutic Approach

Archive: 2011

Ritter Pharmaceuticals Appoints Robert H. Tidwell to Chief Business Officer

LOS ANGELES – December 8, 2011 – Ritter Pharmaceuticals, Inc. (Ritter Pharma) has appointed Robert H. Tidwell as chief business officer. Mr. Tidwell brings over 30 years of biotechnology and pharmaceutical industry experience to Ritter Pharma as the Company prepares to partner its proprietary Phase 2 compound, RP-G28, for the treatment of lactose intolerance. Mr. […]

Leave Your Comments »

Ritter Pharmaceuticals Completes Phase 2 Trial for Lactose Intolerance

–Company Expects to Announce Phase 2 Clinical Data In First Quarter of 2012– LOS ANGELES – November 17, 2011 – Ritter Pharmaceuticals, Inc. (Ritter) announced today the last patient has completed treatment in its Phase 2 study for RP-G28, a first-in-class treatment for symptoms associated with lactose intolerance. This multicenter, randomized, double-blind, placebo-controlled, parallel group […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Announces First Patient Enrollment in its Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance

LOS ANGELES, CA – June 21, 2011 – Ritter Pharmaceuticals, Inc. (Ritter), a pharmaceutical company with a focus on digestive diseases, announced today that clinical investigators have enrolled the first patient in its randomized, double-blind, placebo-controlled Phase 2 study of RP-G28 in patients with symptoms associated with lactose intolerance. The study, which is being conducted […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD